Soligenix Inc. - Asset Resilience Ratio
Soligenix Inc. (SNGX) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Soligenix Inc.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2017)
This chart shows how Soligenix Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SNGX current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Soligenix Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SNGX current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Soligenix Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Soligenix Inc. Industry Peers by Asset Resilience Ratio
Compare Soligenix Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Soligenix Inc. (1999–2017)
The table below shows the annual Asset Resilience Ratio data for Soligenix Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $9.55 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $10.27 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $7.39 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $6.95 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $8.27 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $4.71 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $8.22 Million | -- |
| 2000-12-31 | 14.74% | $2.01 Million | $13.67 Million | -23.52pp |
| 1999-12-31 | 38.26% | $3.55 Million | $9.27 Million | -- |
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the tre… Read more